Regenic Ltd Competitors

Biomedix is a provider of front-line diagnostic solutions for delivering value-based care. We offer a mobile health assessment platform that centralizes data for analyzing population health across multiple chronic conditions, and supports a variety of diagnostic devices. Biomedix is the maker of PADnet, the market leader in front-line diagnostics for peripheral vascular disease. PADnet is the only diagnostic device that can support the identification of peripheral artery disease (PAD) and chronic venous insufficiency (CVI) through a unique collaborative care model, which enables the cost-effective delivery of care that optimizes patient outcomes.

Eureka helps doctors start their own practice and see their first patients in days, not months. We're backed by top healthcare funds and advisors/angels including Khosla Ventures, Bling Capital, and the founders of 23andMe, Forward Health, Opendoor, Clubhouse, Counsyl, Paypal, etc.

About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com. About the Neuro-Spinal Scaffold™ Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.